Arsanis

Arsanis is a clinical-stage biotechnology company. Its leading targeted monoclonal antibody (mAb) is being developed for preventive treatment and addressing severe infectious diseases. The company’s current therapeutic approach aims to selectively target pathogenic processes rather than broadly eliminating pathogens, potentially allowing critical infections to be addressed without contributing to drug resistance issues.